Quick Answer
Cartesian Therapeutics, Inc. reported Net Income Loss of -$130.30 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -68.3% in Net Income Loss from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$6.92 million | Q3 2016: -$7.73 million | Q4 2016: -$14.08 million | Q1 2017: -$15.13 million | Q2 2017: -$15.97 million | Q3 2017: -$14.68 million | Q4 2017: -$19.54 million | Q1 2018: -$15.89 million | Q2 2018: -$18.80 million | Q3 2018: -$16.00 million | Q4 2018: -$14.65 million | Q1 2019: -$12.07 million | Q2 2019: -$16.39 million | Q3 2019: -$11.99 million | Q4 2019: -$14.89 million | Q1 2020: -$19.62 million | Q2 2020: -$24.08 million | Q3 2020: -$9.73 million | Q1 2021: -$24.60 million | Q2 2021: $4.57 million | Q3 2021: -$17.89 million | Q1 2022: $28.78 million | Q2 2022: $8.60 million | Q3 2022: -$7.89 million | Q1 2023: -$21.66 million | Q2 2023: -$11.39 million | Q3 2023: -$9.00 million | Q1 2024: -$56.82 million | Q2 2024: $13.84 million | Q3 2024: -$24.18 million | Q1 2025: -$17.71 million | Q2 2025: $15.89 million | Q3 2025: -$35.90 million.
- Over the full 12 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Net Income Loss has declined by 911.7%.
- Historical annual values: Fiscal year 2025: -$130.30 million | Fiscal year 2024: -$77.42 million | Fiscal year 2023: -$219.71 million | Fiscal year 2022: $35.38 million | Fiscal year 2021: -$25.69 million | Fiscal year 2020: -$68.88 million | Fiscal year 2019: -$55.35 million | Fiscal year 2018: -$65.34 million | Fiscal year 2017: -$65.32 million | Fiscal year 2016: -$36.21 million | Fiscal year 2015: -$25.17 million | Fiscal year 2014: -$12.88 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: